Oxbow Advisors LLC Acquires 450 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Oxbow Advisors LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 71,941 shares of the biopharmaceutical company’s stock after acquiring an additional 450 shares during the quarter. Oxbow Advisors LLC’s holdings in Gilead Sciences were worth $6,645,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $29,000. Finally, Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $31,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 713,000 shares of company stock valued at $67,945,181 in the last 90 days. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on GILD. Oppenheimer boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Wells Fargo & Company boosted their price objective on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Robert W. Baird boosted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Trading Down 0.1 %

NASDAQ GILD opened at $109.95 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $111.03. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50-day moving average of $95.41 and a 200-day moving average of $88.63. The firm has a market cap of $137.03 billion, a PE ratio of 297.16, a price-to-earnings-growth ratio of 0.90 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.94 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is presently 832.43%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.